PROJECT STAGE
Preclinical Development
Lead Optimisation
Lead Generation
Early Discovery
Therapeutic area Alzheimer’s Disease
Background info
Indication
Advantages
Intellectual property
Owner/lead

Project Aim

To develop a humanised antibody that specifically targets toxic species of Aβ for Alzheimer’s Disease

Advantage

A novel approach to specifically target Aβ N-terminal oligomers

Target Class

Extracellular Protein

Modality

Antibody

Current Status

Lead with in-vivo proof of concept

Intellectual Property

Existing patent applications with scope for additional IP protection

Offering

Licence or collaboration for preclinical / clinical development

Key Contact

  • Hidden
  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email support@thewebkitchen.co.uk.
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
All Licensing Opportunities